Company intelligence / Profile preview

BiOptic

San Francisco, California, United Statesbioptic.com.tw ↗

Ownership: Public · 6850
Development stage: Commercial

Overview

BiOptic operates an advanced vertical agent-based artificial intelligence platform that autonomously triages, assesses, and prioritizes drug assets for oncology—currently with a primary focus on prostate cancer. Their proprietary models predict potency, safety, manufacturability of molecules and automate diligence processes. As of June 2025 there are no reported clinical results or late-stage pipeline assets.

Therapeutic areas: Oncology
Modalities: Small moleculeAI-driven drug candidate identification
Industry: Drug Discovery Services

Beyond the preview

Go deeper on BiOptic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiOptic.

Explore the full profile